Many researches have shown that coronavirus infection can lead to
neurological symptoms. The most common symptom is headache.
Calcitonin gene-related peptide (CGRP), which has an important role in
the pathophysiology of migraine, may have an active role in persistent
headaches after COVID, due to the structural similarity between the CGRP
receptor and the SARS-CoV-2 spike protein. In this case report, the effect
of the anti-CGRP monoclonal antibody on the migraine attack occurring
after COVID-19 m-RNA vaccine will be discussed. A 55-year-old female
patient who is followed up with a diagnosis of chronic migraine, had
severe and throbbing headache that started after the COVID-19 m-RNA
vaccine. After galcanezumab (CGRP monoclonal antibody – CGRP mAb)
was started in the patient whose complaints did not regress despite the
adjustment of the current drug doses, clinically significant improvement
was observed in her complaints after the first dose and it was planned to
continue with 120 mg CGRP mAb per month in her follow-ups.
Keywords: CGRP monoclonal antibody, coronavirus, galcanezumab,
migraine